Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials
Patients in SPOTLIGHT and GLOW maintained measured HRQoL relative to baseline when treated with first-line zolbetuximab added to chemotherapy. Zolbetuximab plus chemotherapy improved PFS and OS without negatively affecting HRQoL in key PRO domains compared with placebo plus chemotherapy.
Authors
- Stephanie Rhoten
- Radhika Ranganath
- K. Shitara
- Michael S. Oh (ORCID: https://orcid.org/0000-0002-7206-771X)
- Jaffer A. Ajani (ORCID: https://orcid.org/0000-0001-9946-0629)
- Florian Lordick (ORCID: https://orcid.org/0000-0001-8591-9339)
- Manali Shah (ORCID: https://orcid.org/0009-0007-4688-375X)
- J.W. Park
- Maria Matsangou
- Rupesh Pophale
- Eric Van Cutsem (ORCID: https://orcid.org/0000-0002-6372-1230)
- Prasun Bhattacharya (ORCID: https://orcid.org/0000-0002-1982-5227)
- Rui‐Hua Xu (ORCID: https://orcid.org/0000-0001-9771-8534)
- Arijit Ganguli (ORCID: https://orcid.org/0009-0000-2569-2734)
- Yaxin Kang (ORCID: https://orcid.org/0009-0009-7585-5250)
- Linda Chang
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Sun Yat-sen University (CN)
- Cornell University (US)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- IQVIA (United States) (US)
- National Cancer Center Hospital East (JP)
- Sun Yat-sen University Cancer Center (CN)
- Astellas Pharma (United States) (US)
- State Key Laboratory of Oncology in South China
- Leipzig University (DE)
- KU Leuven (BE)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103663
- Citations
- 22
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 9.22
Funders
- Astellas Pharma US
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders